Trihexyphenidyl
As of the edition of 20 October 2026, Trihexyphenidyl is a small molecule: marketed, first approved in 1962 (ES); acts on CHRM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Artane
- First approved
- 1 November 1962 (ES)
- Approvals on record
- 9 in 4 regions
- Holder of the most recent approval
- RICHARD; 4 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Nervous system; Cancer; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Earlier holder |